i3 Energy (I3E), an independent oil and gas company, said it is moving from a bi-annual to a monthly schedule for its dividend payments. The company said its predictable, low-decline assets continue to outperform management’s expectations, and it is forecasting robust cash flow generation from its production business following an intense period of accretive growth since mid-2020 entry into the Western Canadian Sedimentary Basin.
By Zak Mir
Caracal Gold (GCAT), the gold producer with operations in East Africa, said it is to accelerate implementation of the final phase of its’ initial three-phase operational plan to further increase gold production and improve efficiencies at its flagship Kilimapesa Gold Mining and Processing Operations in Kenya. The decision to accelerate the third phase development activities at the Kilimapesa Gold Mining and Processing Operations and increase production to approx. 24,000oz p.a. follows the successful completion of the first two phases of operational improvements and developments since listing in August 2021.
Love Hemp Group (LIFE), the brand-led consumer goods company, announced that Garry Cook and Graham Mullis will be joining the Board of Love Hemp as Non-Executive Directors from 14 February 2022. These appointments are being made to support and enhance Love Hemp’s corporate positioning and governance and to prepare for the Company’s planned move to the Main Market of the London Stock Exchange.
Rambler Metals and Mining (RMM), a copper and gold producer, explorer and developer, has raised gross proceeds of £3,833,643.70 at a price of 26.5p. The funds raised will be used to underwrite ongoing underground development and for working capital. This Placing is in support of mining production expansion to a sustained 1,350 tpd at 2% copper and has positioned the company to reach full mill production by the end of the first quarter of 2022.
Omega (ODX), the specialist medical diagnostics company, currently involved for some in a guess the placing competition, said that it has successfully CE marked its VISITECT® COVID-19 antigen test for self-test use. The test will provide consumers with an accurate rapid test for the detection of the nucleoprotein of the SARS-CoV-2 virus in nasal swabs only. The VISITECT® COVID-19 antigen test has excellent performance characteristics following independent multi-centre validations, with sensitivity of 93.2% based on 103 samples with cycle threshold (Ct) values <25, and 97.8% specificity, based on 230 RT-qPCR negative samples.
Itaconix (ITX), a specialist in plant-based specialty polymers, is extending its technology platform into potential uses in composite materials and has filed a new patent to protect innovative intellectual property for expected applications in this new area. The extension of the Itaconix technology platform is part of the company’s efforts to engage with potential customers to identify sizable unmet needs that Itaconix can address with plant-based solutions.
Cizzle Biotechnology (CIZ), the UK based diagnostics developer, announced that following the signing of a Memorandum of Understanding with the International Co-Innovation Centre for Advanced Medical Technology and Shenzhen Intelliphecy Life Technologies Co., Ltd., announced on 25 November 2021, a full commercial agreement has now been executed to develop and market the Company’s proprietary early lung cancer diagnostic tests in China.
Avacta Group (AVCT), a clinical stage oncology drug company, announced that the first-in-human Phase I trial (ALS-6000-101) of AVA6000 Pro-doxorubicin will advance to the next dose cohort following a positive review of the safety data from the dosing of the first cohort. Avacta’s Safety Data Monitoring Committee has completed its review of the safety data from the first cohort dosed with AVA6000 at 80mg/m2 in the ongoing Phase I trial. Following this review, the SDMC has recommended that the clinical trial continues as planned and escalates to the next dose of AVA6000 at 120mg/m2.
Trident Royalties (TRR), update on its activities undertaken during the quarter ended 31 December 2021, including Q4 royalty receipts. The company said that this has been its most significant quarter to date and sets the company up for what I am convinced will be an exciting year to come. The number of producing assets within the portfolio increased by 350% in the quarter – increasing not only the scale but, importantly, the diversification of its portfolio.
ECR Minerals (ECR), the gold exploration and development company, announced that exploration licences EPM27901, EPM27902 and EPM27903 have been granted to its subsidiary LUX Exploration Limited, in the Lolworth Region, North Queensland. LUX is a wholly owned subsidiary of ECR with a specific focus on exploration projects in the North Queensland region in Australia.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates.
Terms of Website Use
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned